Multiple daily doses of acetyl-salicylic acid (ASA) overcome reduced platelet response to once-daily ASA after coronary artery bypass graft surgery: A pilot randomized controlled trial

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 3, 2015, Pages 448-456

  Paikin, J S ^a   Hirsh, J ^a   Ginsberg, J S ^a   Weitz, J I ^a   Chan, N C ^a   Whitlock, R P ^a   Pare, G ^a   Johnston, M ^a   Eikelboom, J W ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Aspirin; Coronary artery bypass; Drug resistance; Perioperative period; Platelet function tests

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; THROMBOXANE A2; THROMBOXANE B2; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; GRAFT FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MIDDLE AGED; MULTIPLE ELECTRODE AGGREGOMETRY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE RICH PLASMA; THROMBOXANE B2 BLOOD LEVEL; TREATMENT OUTCOME; ADVERSE EFFECTS; BLOOD; BLOOD CLOTTING PARAMETERS; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; ONTARIO; PILOT STUDY; THROMBOCYTE; TIME FACTOR;

AGED; ASPIRIN; BIOMARKERS; BLOOD PLATELETS; CORONARY ARTERY BYPASS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; ONTARIO; PILOT PROJECTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET FUNCTION TESTS; THROMBOXANE B2; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923668753     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12832     Document Type: Article

References (28)

1. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998; 97: 916-31.
2. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT, PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 2005; 294: 2446-54.
3. McEnany MT, Salzman EW, Mundth ED, DeSanctis RW, Harthorne JW, Weintraub RM, Gates S, Austen WG. The effect of antithrombotic therapy on patency rates of saphenous vein coronary artery bypass grafts. J Thorac Cardiovasc Surg 1982; 83: 81-9.
4. Sharma GV, Khuri SF, Josa M, Folland ED, Parisi AF. The effect of antiplatelet therapy on saphenous vein coronary artery bypass graft patency. Circulation 1983; 68: II218-21.
5. Brown BG, Cukingnan RA, DeRouen T, Goede LV, Wong M, Fee HJ, Roth JA, Carey JS. Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery. Circulation 1985; 72: 138-46.
6. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Doherty J, Read R, Chesler E, Sako Y. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a veterans administration cooperative study. Circulation 1988; 77: 1324-32.
7. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Doherty J, Read R, Chesler E, Sako Y. Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a veterans administration cooperative study. Circulation 1989; 80: 1190-7.
8. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Kern KB, Sethi G, Sharma GV, Khuri S. Long-term graft patency (3 years) after coronary artery surgery. Effects of aspirin: results of a VA cooperative study. Circulation 1994; 89: 1138-43.
9. Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation 1991; 83: 1526-33.
10. Zimmermann N, Kienzle P, Weber AA, Winter J, Gams E, Schror K, Hohlfeld T. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 121: 982-4.
11. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, Schror K, Hohlfeld T. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-7.
12. Zimmermann N, Kurt M, Wenk A, Winter J, Gams E, Hohlfeld T. Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting? Eur J Cardiothorac Surg 2005; 27: 606-10.
13. Zimmermann N, Kurt M, Winter J, Gams E, Wenzel F, Weber AA, Hohlfeld T. Aspirin-induced platelet inhibition in patients undergoing cardiac surgery. Platelets 2007; 18: 528-34.
14. Zimmermann N, Kurt M, Winter J, Gams E, Wenzel F, Hohlfeld T. Detection and duration of aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2008; 135: 947-8.
15. Bednar F, Osmancik P, Hlavicka J, Jedlickova V, Paluch Z, Vanek T. Aspirin is insufficient in inhibition of platelet aggregation and thromboxane formation early after coronary artery bypass surgery. J Thromb Thrombolysis 2009; 27: 394-9.
16. Gluckman TJ, McLean RC, Schulman SP, Kickler TS, Shapiro EP, Conte JV, McNicholas KW, Segal JB, Rade JJ. Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. J Am Coll Cardiol 2011; 57: 1069-77.
17. Yilmaz MB, Balbay Y, Caldir V, Ayaz S, Guray Y, Guray U, Korkmaz S. Late saphenous vein graft occlusion in patients with coronary bypass: possible role of aspirin resistance. Thromb Res 2005; 115: 25-9.
18. Golanski J, Chlopicki S, Golanski R, Gresner P, Iwaszkiewicz A, Watala C. Resistance to aspirin in patients after coronary artery bypass grafting is transient: impact on the monitoring of aspirin antiplatelet therapy. Ther Drug Monit 2005; 27: 484-90.
19. Arazi HC, Doiny DG, Torcivia RS, Grancelli H, Waldman SV, Nojek C, Fornari MC, Badimon JJ. Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgery. Interact Cardiovasc Thorac Surg 2010; 10: 863-7.
20. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-83.
21. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61: 314-9.
22. Di Minno G, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 1983; 61: 1081-5.
23. Di Minno G, Violi F. Aspirin resistance and diabetic angiopathy: back to the future. Thromb Res 2004; 113: 97-9.
24. Di Minno MN, Lupoli R, Palmieri NM, Russolillo A, Buonauro A, Di Minno G. Aspirin resistance, platelet turnover, and diabetic angiopathy: a 2011 update. Thromb Res 2012; 129: 341-4.
25. Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, Pocaterra D, Ragazzoni E, Rolandi G, Rocca B, Patrono C. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012; 119: 3595-603.
26. Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, Lattanzio S, Mattoscio D, Zaccardi F, Liani R, Vazzana N, Del Ponte A, Ferrante E, Martini F, Cardillo C, Morosetti R, Mirabella M, Ghirlanda G, Davi G, Patrono C. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012; 10: 1220-30.
27. Spectre G, Arnetz L, Ostenson CG, Brismar K, Li N, Hjemdahl P. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost 2011; 106: 491-9.
28. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336: 195-8.